Broadwood Partners Issues Letter to STAAR Surgical’s Board Questioning Its Judgment in Proposed Sale to Alcon

Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA). Broadwood, which owns 27.5% of STAAR’s outstanding common shares, continues to urge its fellow shareholders to vote on its GREEN Proxy Card “AGAINST” the proposed acquisition of STAAR by Alcon Inc. (“Alcon”) (NYSE: ALC).

Shareholders can find additional information at www.LetSTAARShine.com.

October 6, 2025

STAAR Surgical Company
25510 Commercentre Dr.
Lake Forest, CA 92630

Dear Members of the Board:

You have decided it is time to sell STAAR for $28 per share. As you know, we strongly disagree with that decision.

One thing we can surely agree on, however, is that this Board is, at best, one-for-two in making decisions about selling STAAR. With hundreds of millions of dollars of shareholder money at stake, that is not good enough.

Sixteen months ago, you decided not to sell the Company to Alcon for $58 per share in cash. You walked away from the table because of your belief in STAAR’s strong business prospects.¹ Yet now, with little change in the market, management’s financial forecasts, or STAAR’s opportunities, you have decided to sell the Company for $28 per share.

“No” to $58.

“Yes” to $28.

As your largest shareholder, we believe the Board got it right the first time.

The Board wants shareholders to believe that its decision to sell the Company now, at less than half the price, was based on a reassessment of the Company’s business performance and outlook. But we cannot fathom how that could be.

The Company had a difficult few quarters, to be sure, as demand in China slowed temporarily and excess inventory was worked off. But now, STAAR’s prospects are sound, with sufficient cash, strong demand, new products ready to be launched, and cost savings opportunities to drive future profitability. In fact, if management’s own projections are achieved, the company will experience double-digit revenue growth and profit margins that are among the highest of any midsized medical technology company in the world. And those projections are consistent with the company’s prospects at the time you rejected $58 per share.